Workflow
Brainsway(BWAY)
icon
Search documents
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
GlobeNewswire News Room· 2024-12-12 13:00
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation (TMS) technology to treat alcohol use disorder (AUD) patients. The outcomes were reported in ...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
GlobeNewswire News Room· 2024-11-20 13:00
BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the publication of positive feasibility clinical data evaluating the analgesic effects of deep transcranial magnetic stimulation (Deep TMS™) in patients with peripheral neuropathic pain. The results were published in the Neuromodulation journal, in a peer ...
Brainsway(BWAY) - 2024 Q3 - Earnings Call Transcript
2024-11-12 17:59
BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Participants Steven Lichtman - Oppenheimer Jeff Cohen - Ladenburg Thalmann & Company Operator Good day, and welcome to the BrainsWay Third Quarter 2024 Earnings Conference Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Brian Ritchie of Life ...
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire News Room· 2024-11-12 12:30
Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported third quarter 2024 financial results and provided an operatio ...
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
GlobeNewswire News Room· 2024-10-29 12:00
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, November 12, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the ...
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 32.01%: Here's is How to Trade
ZACKS· 2024-10-21 14:55
Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 24.2% over the past four weeks to close the last trading session at $10.06, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.28 indicates a potential upside of 32%.The mean estimate comprises four short-term price targets with a standard deviation of $1.84. While the lowest estimate of $12 indicates a 19.3% increase fr ...
Here's Why Momentum in Brainsway (BWAY) Should Keep going
ZACKS· 2024-10-21 13:50
When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
ZACKS· 2024-10-15 14:45
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Brainsway Ltd. Sponsored ADR (BWAY) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Brainsway Ltd. Sponsored ADR is a member of the Medical sector. This group includes 1025 individual stocks and currently holds a Zacks Sector Rank of #3. The Z ...
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
GlobeNewswire News Room· 2024-10-09 11:30
BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the further expansion of its Deep Transcranial Magnetic Stimulation (Deep TMS™) platform in East Asia through the placement of 15 new systems in Taiwan and South Korea. "The recent orders for 15 additional Deep TMS systems to be used by mental health cent ...
Does Brainsway (BWAY) Have the Potential to Rally 34.38% as Wall Street Analysts Expect?
ZACKS· 2024-10-04 14:56
Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $9.60, gaining 30.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.90 indicates a 34.4% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $2.17. While the lowest estimate of $11 indicates a 14.6% increase from the current price level, the most optimist ...